Thursday, April 29, 2021

Capsida Uncloaks With $140M In Funding

Thousand Oaks-based Capsida Biotherapeutics, a new biotechnology company focused on using adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, has uncloaked from stealth mode, saying it has raised $140M in total capital. The startup is backed by $50M in a Series

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.

---